Evotec begins construction on Toulouse biologics manufacturing facility

By The Science Advisory Board staff writers

April 20, 2021 -- Evotec will soon break ground on its first commercial biologics manufacturing facility in Europe at its Campus Curie in Toulouse, France.

Construction is expected to commence in the second half of this year on the facility, which will support the development and manufacturing of therapeutic antibodies for the treatment of infectious diseases, such as COVID-19, upon its planned completion in 2023, Evotec said.

The company's initial biologics manufacturing facility is nearing completion in Redmond, WA, and is scheduled to be fully operational in the second half of 2021.

If you like this content, please share it with a colleague!

Related Reading

Evotec, Takeda partner on RNA-targeting drug discovery, development
Evotec has entered into an alliance with Takeda Pharmaceutical with the goal of discovering and developing RNA-targeting small-molecule therapeutics for...

Eveotec, Indivumed partner on novel lung cancer therapies
Evotec and Indivumed announced on January 23 a partnership to collaborate on drug discovery and development of novel therapies for non-small cell lung...

Evotec, Bayer partner for drug discovery in women's health
Evotec and Bayer announced on January 9 the expansion of their partnership in women's health with a new five-year, multitarget collaboration with participation...